Abstracts tagged "mouse model and treatment"

Abstract Number: 2620 • 2019 ACR/ARP Annual Meeting
Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model
Yuka Oikawa¹, Kohei Yamauchi ² and Makoto Maemondo ¹, ¹Iwate Medical University School of Medicine, Morioka, Japan, Division of Pulmonary medicine, Allergy and Rheumatology, Department of Internal Medicine, morioka, Japan, ²Takizawa central Hospital, morioka, Japan
Background/Purpose: We reported allergic granulomatous vasculitis with eosinophil infiltration in an asthma model of C57BL/6 sensitized with ovalbumin (OVA). TGF-btea and IL-6 are thought to…
Abstract Number: 1749 • 2016 ACR/ARHP Annual Meeting
The Role of Mucosal-Associated Invariant T (MAIT) Cells in Lupus Dermatitis
Goh Murayama¹, Asako Chiba², Hirofumi Amano³, Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake⁴, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan, ⁴Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by MHC-related molecule-1 (MR1) and express a semi-invariant TCRa chain: Va7.2-Ja33 in…
Abstract Number: 1503 • 2013 ACR/ARHP Annual Meeting
The Suppressive Ability Of Altered Peptide Ligands To M3R Reactive T Cells In M3R Induced Autoimmune Sialadenitis
Hiromitsu Asashima¹, Hiroto Tsuboi¹, Naomi Matsuo¹, Chihiro Hagiya¹, Tomoya Hirota¹, Mana Iizuka¹, Yuya Kondo¹, Isao Matsumoto² and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Previous studies have shown that Rag1-/- mice transferred with splenocytes of M3 muscarinic acetylcoline receptor (M3R)-/- mice immunized with M3R peptides mixture (three N-terminal…
Abstract Number: 540 • 2013 ACR/ARHP Annual Meeting
Exploration Of a Novel Therapeutic Target In a Murine Model Of Systemic Lupus Erythematosus: Targeting Sphingosine-1-Phosphate (S1P) Receptors
Christopher Tracy¹, Jess Edison², S. Frattalone² and C. Moratz³, ¹Internal Medicine-Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ³Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by symptomatic flares that often result in terminal organ failure. The pathogenesis is characterized by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].